| Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript |
Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. |
seekingalpha.com |
2025-05-15 00:29:34 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results |
Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 14, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 third quarter. |
accessnewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 |
DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025, after the market close on Wednesday, May 14, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, May 14, 2025, at 4:30 p.m. |
accessnewswire.com |
2025-05-07 20:15:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 |
Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pacific time (4:30 p.m. |
accessnewswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript |
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only. |
seekingalpha.com |
2025-02-12 20:27:51 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results |
Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter. |
accessnewswire.com |
2025-02-12 18:03:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 |
DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, February 12, 2025, at 4:30 p.m. |
accessnewswire.com |
2025-02-05 19:50:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The fireside chat will take place at 10:00 a.m. |
accesswire.com |
2025-01-06 11:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Disclosure Notification |
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL. |
accesswire.com |
2024-12-04 01:45:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) |
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. "We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. |
accesswire.com |
2024-11-22 11:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript |
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. |
seekingalpha.com |
2024-11-13 21:25:51 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results |
Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow Ryan Selhorn promoted to Chief Financial Officer Company to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 first quarter. |
accesswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 |
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. |
accesswire.com |
2024-11-06 19:20:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit |
DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time. |
accesswire.com |
2024-10-14 20:15:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada |
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, and Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of global pharma major Lupin Limited, today announced the signing of an exclusive collaboration, distribution and supply agreement for Aytu's Adzenys XR-ODT® and Cotempla XR-ODT® product lines in Canada. Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder ("ADHD") in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. |
accesswire.com |
2024-10-01 12:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript |
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode. |
seekingalpha.com |
2024-09-26 22:51:03 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results |
Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levels Company to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2024 full year and fourth quarter. |
accesswire.com |
2024-09-26 20:15:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 |
DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m. |
accesswire.com |
2024-09-19 21:30:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 |
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024. Webcast The webcasted fireside chat will take place at 12:15 p.m. |
accesswire.com |
2024-08-08 21:20:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations |
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / ACCESSWIRE / August 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that following the wind down of operations, it has entered into a definitive agreement to divest its Consumer Health (a/k/a Innovus Pharmaceuticals) business to a private, e-commerce focused company. The divested business encompasses the established e-commerce platform, certain inventory and associated consumer brands, intellectual property, contracts and liabilities, and provides for Aytu to receive revenue-based royalty payments on future sales of former Consumer Health business products. |
accesswire.com |
2024-08-06 12:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms |
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan Term loan maturity extended to June 12, 2028 Extension of Revolving Credit Facility increases potential borrowing capacity DENVER, CO / ACCESSWIRE / June 18, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company. In addition, the Company received $3.5 million of additional capital through the exercise of warrants from its June 2023 equity financing, a portion of which was used to pay down the term loan indebtedness. |
accesswire.com |
2024-06-18 12:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript |
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode. |
seekingalpha.com |
2024-05-16 00:28:09 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results |
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business $19.8 million cash balance at March 31, 2024 Company to host conference call and webcast today, May 15, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / May 15, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. |
accesswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 |
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. |
accesswire.com |
2024-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 |
Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference. |
accesswire.com |
2024-04-03 13:00:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript |
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript |
seekingalpha.com |
2024-02-15 00:52:09 |
Czytaj oryginał (ang.) |
| Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter |
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023 $19.5 million cash balance at December 31, 2023 Company to host conference call and webcast today, February 14, 2024 at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. |
accesswire.com |
2024-02-14 18:05:00 |
Czytaj oryginał (ang.) |
| Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 |
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024, at 4:30 p.m. |
accesswire.com |
2024-02-07 18:15:00 |
Czytaj oryginał (ang.) |